OCUL vs. AUPH, ARCT, PLRX, LBPH, ALXO, SAGE, PRTC, NRIX, DNTH, and BCYC
Should you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Aurinia Pharmaceuticals (AUPH), Arcturus Therapeutics (ARCT), Pliant Therapeutics (PLRX), Longboard Pharmaceuticals (LBPH), ALX Oncology (ALXO), Sage Therapeutics (SAGE), PureTech Health (PRTC), Nurix Therapeutics (NRIX), Dianthus Therapeutics (DNTH), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical preparations" industry.
Aurinia Pharmaceuticals (NASDAQ:AUPH) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability.
Aurinia Pharmaceuticals presently has a consensus target price of $10.00, indicating a potential upside of 96.08%. Ocular Therapeutix has a consensus target price of $17.60, indicating a potential upside of 185.25%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.
In the previous week, Aurinia Pharmaceuticals had 7 more articles in the media than Ocular Therapeutix. MarketBeat recorded 11 mentions for Aurinia Pharmaceuticals and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.49 beat Aurinia Pharmaceuticals' score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.
Aurinia Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.
36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Aurinia Pharmaceuticals has a net margin of -32.69% compared to Aurinia Pharmaceuticals' net margin of -138.15%. Ocular Therapeutix's return on equity of -14.79% beat Aurinia Pharmaceuticals' return on equity.
Aurinia Pharmaceuticals received 143 more outperform votes than Ocular Therapeutix when rated by MarketBeat users. Likewise, 73.07% of users gave Aurinia Pharmaceuticals an outperform vote while only 69.74% of users gave Ocular Therapeutix an outperform vote.
Summary
Aurinia Pharmaceuticals beats Ocular Therapeutix on 10 of the 18 factors compared between the two stocks.
Get Ocular Therapeutix News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocular Therapeutix Competitors List
Related Companies and Tools
